Clinical Trials on Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer in Japan
Total 97 results
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Osaka Medical CollegeTerminatedBreast Cancer | HER-2 Positive Breast Cancer | Estrogen Receptor Negative NeoplasmJapan
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
AstraZenecaActive, not recruitingHormone Receptor Positive Breast CancerCanada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
-
Kyoto Breast Cancer Research NetworkPfizerCompletedHormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleTaiwan, Japan, Korea, Republic of, Australia, Hong Kong
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Tokyo Medical and Dental UniversityRecruitingBreast Cancer | Metastatic Breast Cancer | OligometastasisJapan
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Tokyo Medical UniversityTokyo University; Saint Luca International HospitalCompleted
-
Eli Lilly and CompanyCompletedBreast Cancer | Metastatic Breast CancerJapan
-
Osaka Medical CollegeCompletedBreast Cancer | Effects of Chemotherapy | HER-2 Positive Breast CancerJapan
-
AstraZenecaCompletedNeoplasms | Breast Cancer | Metastatic CancerJapan
-
National Cancer Center, JapanH.U. Group Research Institute G.K.RecruitingHER2-positive Breast CancerJapan
-
Chugai PharmaceuticalCompleted
-
Nippon Kayaku Co., Ltd.CompletedBreast Cancer Nos Metastatic RecurrentJapan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalCompletedMetastatic Breast CancerJapan
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States, Japan
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
-
Eli Lilly and CompanyCompletedMetastatic Breast CancerJapan
-
Eli Lilly and CompanyCompletedMetastatic Breast CancerJapan
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
PfizerCompleted
-
R-PharmCompleted
-
Daiichi Sankyo Co., Ltd.Daiichi Sankyo, Inc.CompletedMetastatic Breast CancerUnited States, Japan
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerJapan
-
BayerActive, not recruitingLiver Metastases | Metastatic Pancreatic Cancer | Gadoxetate Sodium-enhanced Magnetic Resonance ImagingJapan
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompletedBreast Cancer | Neoplasm MetastasisJapan
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico, Korea, Republic of
-
M.D. Anderson Cancer CenterTerminatedBreast CancerUnited States, Japan
-
Novartis PharmaceuticalsRecruitingMetastatic Breast CancerUnited States, Lebanon, Hong Kong, Turkey, Vietnam, Brazil, Italy, South Africa, Korea, Republic of, Poland, Taiwan, Singapore, Japan, Spain, Costa Rica, Greece, Portugal, Argentina, Mexico
-
PfizerAstraZenecaCompletedMetastatic Breast CancerKorea, Republic of, United States, Canada, United Kingdom, Australia, Taiwan, Netherlands, Italy, Japan, Belgium, Ireland, Ukraine, Portugal, Germany, Romania, Russian Federation, Turkey
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Hoffmann-La RocheCompletedMetastatic Breast CancerUnited States, Korea, Republic of, United Kingdom, Italy, Russian Federation, Argentina, Belgium, Brazil, Panama, Germany, Japan, Ukraine, Chile, South Africa, Bulgaria, Romania
-
SanofiActive, not recruitingBreast Cancer MetastaticKorea, Republic of, Belgium, Taiwan, China, France, United States, Argentina, Australia, Brazil, Canada, Czechia, Greece, Israel, Italy, Japan, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey, Ukraine
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Eli Lilly and CompanyAvailableMetastatic Breast CancerAustralia, Canada, Egypt, India, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom
-
PfizerCompletedMetastatic Breast CancerKorea, Republic of, Serbia, Argentina, Brazil, Japan, Peru, Turkey, United States, Slovakia, Mexico, Philippines, Poland, Romania, Hungary, India, Portugal, South Africa, Latvia, Thailand, Russian Federation, Ukraine, Chile, Czechia, ...
-
Genentech, Inc.Hoffmann-La RocheCompletedMetastatic Breast CancerUnited States, Canada, China, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Spain, United Kingdom, Brazil, Guatemala, Japan, Russian Federation, Singapore, Thailand, Latvia, Argentina, Poland, Ecuador, Mexico, Croatia and more
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia